InMed Pharmaceuticals Inc. (INM)
NCM · Drug Manufacturers - Specialty & Generic
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Peers in Drug Manufacturers - Specialty & Generic
All in industry →Takeda Pharmaceutical Company Limited
Zoetis Inc.
Haleon plc
Teva Pharmaceutical Industries Limited
United Therapeutics Corporation
Viatris Inc.
Regencell Bioscience Holdings Limited
Neurocrine Biosciences, Inc.
Elanco Animal Health Incorporated
Dr. Reddy's Laboratories Limited
Recent press releases
March 2026
InMed Pharmaceuticals Inc. — 8-K Filing
# 🧾 What This Document Is This is an **8-K filing** with a key **Exhibit 99.1** attached. Think of an 8-K as a "current report" companies use to announce major, time-sensitive news to investors. This specific announcement is a formal notification from the Nasdaq stock exchange. 👉 **In simple term
SEC filings
All filings →Insider trades
All insider trades →InMed Pharmaceuticals Inc. has no reported insider trades in the last 90 days.